abs357.txt	objectives		neoadjuvant	chemotherapy	(nact)	versus	primary	debulking	surgery(pds)	for	advanced	epithelial	ovarian	cancer	(aeoc)	remains	controversial	in	theunited	states		generalizability	of	existing	trial	results	has	been	criticizedbecause	of	less	aggressive	debulking	procedures	than	commonly	used	in	the	unitedstates		as	a	result		economic	evaluations	using	input	data	from	these	trials	maynot	accurately	reflect	costs	and	outcomes	associated	with	more	aggressive	primarysurgery		using	data	from	an	ongoing	trial	performing	aggressive	debulking		weinvestigated	the	cost-effectiveness	and	cost-utility	of	nact	versus	pds	for	aeoc	methods		a	decision	tree	model	was	constructed	to	estimate	differences	inshort-term	outcomes	and	costs	for	a	hypothetical	cohort	of	15	000	aeoc	patients(us	annual	incidence	of	aeoc)	treated	with	nact	versus	pds	over	a	1-year	timehorizon	from	a	medicare	payer	perspective		outcomes	included	costs	percancer-related	death	averted		life-years	and	quality-adjusted	life-years	(qalys)gained		base-case	probabilities		costs		and	utilities	were	based	on	the	surgicalcomplications	related	to	primary	or	interval	debulking	in	ovarian	neoplasmstrial		base-case	analyses	assumed	equivalent	survival		threshold	analysisestimated	the	maximum	survival	difference	that	would	result	in	nact	beingcost-effective	at	$50	000/qaly	and	$100	000/qaly	willingness-to-pay	thresholds	probabilistic	sensitivity	analysis	was	used	to	characterize	model	uncertainty	results		compared	with	pds		nact	was	associated	with	$142	million	in	costsavings		1098	fewer	cancer-related	deaths		and	1355	life-years	and	1715	qalysgained		making	it	the	dominant	treatment	strategy	for	all	outcomes		insensitivity	analysis		nact	remained	dominant	in	99	3%	of	simulations		neoadjuvantchemotherapy	remained	cost-effective	at	$50	000/qaly	and	$100	000/qalywillingness-to-pay	thresholds	if	survival	differences	were	less	than	2	7	and	1	4months		respectively	conclusions		in	the	short	term		nact	is	cost-saving	with	improved	outcomes	however		if	pds	provides	a	longer-term	survival	advantage		it	may	becost-effective		research	is	needed	on	the	role	of	patient	preferences	intradeoffs	between	survival	and	quality	of	life	
